| CAS NO: | 178606-66-1 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Molecular Weight (MW) | 309.32 |
|---|---|
| Formula | C13H12FN3O3S |
| CAS No. | 178606-66-1 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 62 mg/mL (200.4 mM) |
| Water: < 1 mg/mL | |
| Ethanol: < 1 mg/mL | |
| Solubility (In vivo) | 30% PEG400+0.5% Tween80+5% propylene glycol: 30 mg/mL |
| Synonyms | MST-104, SLC0111; SLC 0111; U-104; NSC 213841; MST104; MST 104; NSC-213841; NSC213841; SLC-0111; U104; U 104. |
| In Vitro | In vitro activity: U-104 (50 μM) blocks the mesenchymal phenotype in the cancer stem cells population in hypoxia condition of 4T1 cells. U-104 (<50 μM) significantly reduces migration in a dose-dependent manner in metastatic MDA-MB-231 LM2-4Luc+ cells , with cells growing as compact colonies similar to parental MDA-MB-231 cells. U-104 possesses aromatic groups at the second nitrogen ureido group. Cell Assay: U-104 (50 μM) blocks the mesenchymal phenotype in the cancer stem cells population in hypoxia condition of 4T1 cells. U-104 (<50 μM) significantly reduces migration in a dose-dependent manner in metastatic MDA-MB-231 LM2-4Luc+ cells , with cells growing as compact colonies similar to parental MDA-MB-231 cells. |
|---|---|
| In Vivo | U-104 (38 mg/kg) inhibits primary tumor growth in the mice implanted orthotopically with MDA-MB-231 LM2-4Luc+ cells. U-104 (19 mg/kg) inhibits metastases formation in the 4T1 experimental metastasis mice model. U-104 (38 mg/kg) significantly delay primary tumor growth and reduces cancer stem cell population in NOD/SCID mice orthotopically implanted with MDA-MB-231 LM2-4Luc+ cells. U-104 (5 mg/mL, oral gavage) shows a significant delay in tumor growth in Balb/c mice orthotopically implanted with 4T1 cells. |
| Animal model | Balb/c mice orthotopically implanted with 4T1 cells. |
| Formulation & Dosage | Dissolved in 55.6% PEG 400, 11.1% ethanol and 33% water; 5 mg/kg; oral gavage |
| References | Cancer Res. 2011 May 1;71(9):3364-76; Oncogene. 2013 Oct 31;32(44):5210-9. |
m.cnreagent.com